0 CHECKOUT

PRODUCT FILTERS

REGION

3
1
1
1
1

COUNTRY

1
1

CATEGORIES

  • 3
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1

PRICE

1
1
4
11

PUBLISHED

0
4
6
11

PRODUCT TYPE

11

Search for: "Shanghai Fosun Pharmaceutical Group Co., Ltd.-Therapeutic Competitors Report"

Domestic Chinese Biopharmaceutical Companies

Whether your organization (or department) views domestic Chinese pharmaceutical companies as a competitor, complementor, or as a catalyst, they are becoming an increasing force in the global healthcare...

Published:  April 2011
Price:  From

Competitor Analysis: Insulin

The Competitive Intelligence Report Insulin as of January 2011 provides a competitor analysis in the development pipeline of novel insulin-based products for treatment of type 1 and 2 diabetes Purchase...

Published:  January 2011
Price:  From

Type 2 Diabetes - Pipeline Review, H1 2016

Type 2 Diabetes - Pipeline Review, H1 2016 Summary ‘Type 2 Diabetes - Pipeline Review, H1 2016’, provides an overview of the Type 2 Diabetes pipeline landscape. The report provides comprehensive...

Published:  April 2016
Price:  From

Non-Small Cell Lung Cancer - Pipeline Review, H1 2016

Non-Small Cell Lung Cancer - Pipeline Review, H1 2016 Summary ‘Non-Small Cell Lung Cancer - Pipeline Review, H1 2016’, provides an overview of the Non-Small Cell Lung Cancer pipeline landscape. The...

Published:  June 2016
Price:  From

Type 2 Diabetes - Pipeline Review, H2 2015

Type 2 Diabetes - Pipeline Review, H2 2015 Summary The report ‘Type 2 Diabetes - Pipeline Review, H2 2015’, provides an overview of the Type 2 Diabetes’s therapeutic pipeline. This report provides...

Published:  December 2015
Price:  From

Type 2 Diabetes - Pipeline Review, H1 2015

Type 2 Diabetes - Pipeline Review, H1 2015 Summary This, ‘Type 2 Diabetes - Pipeline Review, H1 2015’, provides an overview of the Type 2 Diabetes’s therapeutic pipeline. This report provides comprehensive...

Published:  February 2015
Price:  From

Non-Small Cell Lung Cancer - Pipeline Review, H1 2015

Non-Small Cell Lung Cancer - Pipeline Review, H1 2015 Summary the, ‘Non-Small Cell Lung Cancer - Pipeline Review, H1 2015’, provides an overview of the Non-Small Cell Lung Cancer’s therapeutic...

Published:  June 2015
Price:  From

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016 Summary ‘Receptor...

Published:  June 2016
Price:  From

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2016

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2016 Summary ‘Receptor...

Published:  June 2016
Price:  From

Global Biosimilars Industry 2015

Biosimilar is a term used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator...

Published:  February 2015
Price:  From

Analyzing the Global Biosimilars Industry 2016

Biosimilars are the officially approved versions of biopharmaceutical products that are manufactured by a different company following the patent expiry of the original product. Also known as subsequent...

Published:  July 2016
Price:  From
Loading Indicator

Our Clients

  • Procter & Gamble Co.
  • Western Union Company
  • Volvo Car Corporation
  • Morgan Stanley
  • SAP SE
  • LG Corporation
  • Roche Diagnostics Ltd.